Dupixent Products-Liability MDL 3180 separates undisputed case-coordination facts from contested claims linking Dupixent to cutaneous T-cell lymphoma. Dupixent is dupilumab, an interleukin-4 receptor alpha antagonist, and cutaneous T-cell lymphoma, or CTCL, is the disputed injury at the center.
The undisputed side covers approval, labeled warnings, and federal coordination. The contested side covers causation, misdiagnosis, and warning adequacy. Readers weighing a claim need both sides kept separate.
Table of Contents
- What MDL 3180 Settled About Coordination
- What Dupixent Is and What the Label Warns
- What Plaintiffs Allege About CTCL
- What the Safety Signal Shows — and Its Limits
- Do You Need Different Proof to Seek Compensation?
What MDL 3180 Settled About Coordination
According to the transfer order from the U.S. Judicial Panel on Multidistrict Litigation, the Panel created In re: Dupixent Products Liability Litigation, MDL No. 3180, on June 4, 2026. The cases were centralized in the District of New Jersey before Judge Zahid N.
Quraishi. The order covered 15 actions across 12 districts plus 7 tag-along actions. The OpenClassActions MDL tracker, citing Panel statistics from September 1, 2026, reported about 38-40 pending federal actions in fall 2026. Centralization organizes pretrial proceedings only. Each plaintiff must still prove individual use, diagnosis, and causation.
What Dupixent Is and What the Label Warns
According to the current label on DailyMed, Dupixent is dupilumab, an interleukin-4 receptor alpha antagonist. The National Library of Medicine DailyMed lists first approval in 2017. It lists indications for moderate-to-severe atopic dermatitis, asthma, nasal polyps, EoE, prurigo nodularis and COPD.
Sanofi Market Access describes warnings for hypersensitivity, eye inflammation, eosinophilic conditions and joint symptoms. The same product information contains no specific warning about CTCL or other lymphoma. Whether that labeling choice was adequate remains disputed.
What Plaintiffs Allege About CTCL
Moffitt Cancer Center describes CTCL as a group that includes mycosis fungoides and Sezary syndrome. Mycosis fungoides usually stays skin-limited and grows slowly. Sezary syndrome also places malignant T-cells in the blood. The plaintiffs' MDL transfer brief, filed February 13, 2026, alleges Dupixent caused, unmasked or accelerated CTCL, including mycosis fungoides and Sezary syndrome. The brief names Regeneron, Sanofi-Aventis U.S.
and Genzyme and alleges failure to warn. Causation and warning adequacy are contested and undecided. Both CTCL forms can resemble severe eczema. That resemblance creates misdiagnosis disputes central to these cases. Sequence matters: severe eczema may precede Dupixent use, while CTCL may emerge later.
What the Safety Signal Shows — and Its Limits
TorHoerman Law's summary of the FDA quarterly signal report says FDA listed Dupixent injection for cutaneous T-cell lymphoma as a FAERS signal. The report covered October-December 2024, was posted March 31, 2025, and stated FDA was evaluating need for regulatory action. The answer from the American Academy of Allergy, Asthma & Immunology describes a 2024 Journal of the American Academy of Dermatology retrospective cohort.
Atopic dermatitis patients prescribed dupilumab had higher odds of later CTCL diagnosis, reported as odds ratio 4.1, 95% CI 2.06-8.19. TorHoerman Law's evidence review notes FAERS signals and retrospective database studies do not prove causation. Reviewers note no prospective randomized trial has definitively resolved whether dupilumab causes CTCL versus initial eczema misdiagnosis. Treatment history alone cannot settle which condition came first.
Do You Need Different Proof to Seek Compensation?
Federal coordination does not award compensation or decide any medical question. Personal-injury compensation still turns on individual records and medical proof.
Keep the MDL headline separate from the proof required for one person. Bring the full timeline to counsel early. Misdiagnosis questions make sequence and biopsy dates central to evaluation.
- Prescription and pharmacy records showing Dupixent use and dates
- Dermatology, biopsy and oncology records showing CTCL diagnosis and type
- Timeline tying skin symptoms, Dupixent start and lymphoma diagnosis